TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
B: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
D: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.
Brief Summary: Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
B: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
C: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
D: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Palliative Care in Heart Failure (PAL-HF)
Brief Summary: The primary aim of the PAL-HF trial is to assess the impact of an interdisciplinary palliative care intervention combined with usual heart failure management on health-related quality of life as measured by the Kansas City Cardiomyopathy Questionnaire and the Functional Assessment of Chronic Illness Therapy with Palliative Care Subscale.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Arm Label: Verbal Information and Discussion; Type: EXPERIMENTAL; Interventions: Other: Verbal Information and Discussion | Intervention Type: OTHER; Name: Verbal Information and Discussion; Assigned to Arm(s): Verbal Information and Discussion | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Active Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Support | Arm Label: Usual HF Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual HF Care | Intervention Type: BEHAVIORAL; Name: Behavioral Support; Assigned to Arm(s): Active Intervention | Intervention Type: BEHAVIORAL; Name: Usual HF Care; Assigned to Arm(s): Usual HF Care
C: Arm Label: Usual heart failure care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care + palliative care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual heart failure care, Behavioral: Interdisciplinary palliative care | Intervention Type: BEHAVIORAL; Name: Usual heart failure care; Assigned to Arm(s): Usual care + palliative care | Intervention Type: BEHAVIORAL; Name: Interdisciplinary palliative care; Assigned to Arm(s): Usual care + palliative care
D: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WASH Benefits Bangladesh: A Cluster Randomized Controlled Trial of the Benefits of Water, Sanitation, Hygiene Plus Nutrition Interventions on Child Growth
Brief Summary: Brief Summary:

The purpose of this study is to measure the independent and combined effects of interventions that improve water quality, sanitation, hand washing, and nutrition on child growth and development in the first years of life.


Options:
A: Arm Label: Sanitation intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Provision of household latrines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Provision of household latrines; Assigned to Arm(s): Sanitation intervention
B: Arm Label: Community behaviour change campaign; Type: EXPERIMENTAL; Interventions: Behavioral: Community behaviour change campaign | Arm Label: No community behaviour change campaign; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community behaviour change campaign; Assigned to Arm(s): Community behaviour change campaign
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: GB (Florestor) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: GRALB | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: GC (placebo) | Intervention Type: DRUG; Name: GB (Florestor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: GRALB; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GC (placebo); Assigned to Arm(s): 3
D: Arm Label: Water quality; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Water quality | Arm Label: Sanitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Sanitation | Arm Label: Hand washing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hand washing | Arm Label: Combined WASH; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Water quality, Sanitation, Hand washing (Combined WASH) | Arm Label: Nutrition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition | Arm Label: Nutrition + Combined WASH; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition, Water quality, Sanitation, Hand washing | Arm Label: Non-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Water quality; Assigned to Arm(s): Water quality | Intervention Type: BEHAVIORAL; Name: Sanitation; Assigned to Arm(s): Sanitation | Intervention Type: BEHAVIORAL; Name: Hand washing; Assigned to Arm(s): Hand washing | Intervention Type: BEHAVIORAL; Name: Water quality, Sanitation, Hand washing (Combined WASH); Assigned to Arm(s): Combined WASH | Intervention Type: BEHAVIORAL; Name: Nutrition; Assigned to Arm(s): Nutrition | Intervention Type: BEHAVIORAL; Name: Nutrition, Water quality, Sanitation, Hand washing; Assigned to Arm(s): Nutrition + Combined WASH

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WASH Benefits Bangladesh: A Cluster Randomized Controlled Trial of the Benefits of Water, Sanitation, Hygiene Plus Nutrition Interventions on Child Growth
Brief Summary: Brief Summary:

The purpose of this study is to measure the independent and combined effects of interventions that improve water quality, sanitation, hand washing, and nutrition on child growth and development in the first years of life.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Sanitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Sanitation; Assigned to Arm(s): Intervention
B: Arm Label: Water quality; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Water quality | Arm Label: Sanitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Sanitation | Arm Label: Hand washing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hand washing | Arm Label: Combined WASH; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Water quality, Sanitation, Hand washing (Combined WASH) | Arm Label: Nutrition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition | Arm Label: Nutrition + Combined WASH; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition, Water quality, Sanitation, Hand washing | Arm Label: Non-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Water quality; Assigned to Arm(s): Water quality | Intervention Type: BEHAVIORAL; Name: Sanitation; Assigned to Arm(s): Sanitation | Intervention Type: BEHAVIORAL; Name: Hand washing; Assigned to Arm(s): Hand washing | Intervention Type: BEHAVIORAL; Name: Water quality, Sanitation, Hand washing (Combined WASH); Assigned to Arm(s): Combined WASH | Intervention Type: BEHAVIORAL; Name: Nutrition; Assigned to Arm(s): Nutrition | Intervention Type: BEHAVIORAL; Name: Nutrition, Water quality, Sanitation, Hand washing; Assigned to Arm(s): Nutrition + Combined WASH
C: Arm Label: Sanitation intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Provision of household latrines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Provision of household latrines; Assigned to Arm(s): Sanitation intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Handwashing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Scaling Up Handwashing Behavior Change | Arm Label: Sanitation Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Total Sanitation and Sanitation Marketing | Arm Label: Combined; Type: EXPERIMENTAL; Interventions: Behavioral: Total Sanitation and Sanitation Marketing, Behavioral: Scaling Up Handwashing Behavior Change | Intervention Type: BEHAVIORAL; Name: Total Sanitation and Sanitation Marketing; Assigned to Arm(s): Combined, Sanitation Intervention | Intervention Type: BEHAVIORAL; Name: Scaling Up Handwashing Behavior Change; Assigned to Arm(s): Combined, Handwashing Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)
Brief Summary: The historical standard treatment for early-stage squamous cell carcinoma of the oropharynx is radiation therapy. Some patients require chemotherapy with the radiation, and some patients require surgery if the tumour or lymph nodes have not responded after radiation.

This study will compare radiation therapy with a new surgical treatment called transoral robotic surgery (TORS). TORS is a new surgical approach using a robot to assist the surgeon in removing the tumour, potentially with fewer side effects than older surgical techniques.


Options:
A: Arm Label: Resection/adjuvant radio(-chemo)therapy; Type: EXPERIMENTAL; Interventions: Procedure: Resection, Radiation: Radiotherapy, Drug: Chemotherapy | Arm Label: Adjuvant radio(-chemo)therapy/salvage neck dissection; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy, Drug: Chemotherapy, Procedure: Salvage neck dissection | Intervention Type: PROCEDURE; Name: Resection; Assigned to Arm(s): Resection/adjuvant radio(-chemo)therapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection, Resection/adjuvant radio(-chemo)therapy | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection, Resection/adjuvant radio(-chemo)therapy | Intervention Type: PROCEDURE; Name: Salvage neck dissection; Assigned to Arm(s): Adjuvant radio(-chemo)therapy/salvage neck dissection
B: Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fluorescence visualization device | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fluorescence visualization device | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): A
D: Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)
Brief Summary: The historical standard treatment for early-stage squamous cell carcinoma of the oropharynx is radiation therapy. Some patients require chemotherapy with the radiation, and some patients require surgery if the tumour or lymph nodes have not responded after radiation.

This study will compare radiation therapy with a new surgical treatment called transoral robotic surgery (TORS). TORS is a new surgical approach using a robot to assist the surgeon in removing the tumour, potentially with fewer side effects than older surgical techniques.


Options:
A: Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection
B: Arm Label: Ligusure assisted neck dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Neck dissection | Arm Label: Conventional neck dissection; Type: OTHER; Interventions: Procedure: Neck dissection | Intervention Type: PROCEDURE; Name: Neck dissection; Assigned to Arm(s): Conventional neck dissection, Ligusure assisted neck dissection
C: Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fluorescence visualization device | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fluorescence visualization device | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses
Brief Summary: Patients with comorbidities have an increased risk of ulcer re-bleeding, especially within the 14 days after first bleeding event. Three-day high dose esomeprazole infusion can prevent peptic ulcer rebleeding after endoscopic therapy. However, the optimal dose of oral esomeprazole is uncertain, especially for high risky patients. This study is to test whether a double dose of oral esomprazole could reduce peptic ulcer rebleeding for patients with Rockall score ≥ 6. Additionally, the second aim of this prospective study was to identify the selection criteria to predict poor fading and residual major stigmata of recent hemorrhage (SRH) or early recurrent bleeding after successful endoscopic hemostasis and high-dose PPI infusion.


Options:
A: Arm Label: Double oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Regular oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Intervention Type: DRUG; Name: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden); Assigned to Arm(s): Control group, Double oral dose, Regular oral dose
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Proton pump inhibitor (lansoprazole) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Proton pump inhibitor (lansoprazole) | Intervention Type: DRUG; Name: Proton pump inhibitor (lansoprazole); Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: omeprazole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pantoprazole; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer
Brief Summary: The purpose of this study is to evaluate the effect of mindfulness based stress reduction intervention in women with breast cancer


Options:
A: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): MBSR
B: Intervention Type: BEHAVIORAL; Name: Mindfulness Meditation-Based Stress Reduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive-Expressive Group Therapy; Assigned to Arm(s): N/A
C: Arm Label: MBSR self care program including weekly sessions; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: MBSR self care program; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MBSR; Assigned to Arm(s): MBSR self care program, MBSR self care program including weekly sessions
D: Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: C